Primary non-hodgkin Lymphomas of the Gastrointestinal Tract (GI-NHL)
|
|
- Lizbeth Willis
- 6 years ago
- Views:
Transcription
1 Portorož, Slovenia, June 15-16, 2007 Falk Symposium 160 Pathogenesis and Clinical Practice in Gastroenterology Primary non-hodgkin Lymphomas of the Gastrointestinal Tract (GI-NHL) Emanuele Zucca, M.D. Istituto Oncologico della Svizzera Italiana Oncology Institute of Southern Switzerland
2 GI-NHL Epidemiology GI tract is the most frequent extranodal site in NHL (20%-40% in clinical series) GI involvement: 50%-70% in postmortem studies The stomach represents 50-75% of the GI tract localisations in western countries The incidence of gastric lymphoma is ~ cases per 100,000 inhabitants in Western Europe Lymphoma affecting the stomach, but not other sites, is associated with previous H. pylori infection IPSID is associated with Campylobacter jejuni
3 Definition of Primary GI Lymphoma Strict criteria for gastric NHL (Dawson, 1961) predominant gastric lesion no lymph nodes no liver or spleen normal blood count Relaxed criteria for gastric NHL (Levin, 1978; Herrmann, 1980) contiguous involvement of liver, spleen, bowel, diaphragm, regional nodes gastric lymphomas as a sole or dominant site of involvement General criteria for extranodal NHL (D Amore, 1991) clinically dominant extranodal component after routine staging procedures no lymph nodes or only minor nodal involvement (i.e., 25% of total tumor volume)
4 GI-NHL: Histologic Classification GI-NHL do not fit into a single category but correspond to the different subtypes described by the WHO classification (only the EATCL is strictly typical of the GIT) B-cell Extranodal Marginal Zone B-cell lymphoma of MALT type (including IPSID) DLCL (including those arising at MALT sites) Mantle cell (Lymphomatous polyposis) Burkitt s Follicular lymphoma other types corresponding to nodal equivalents T-cell Enteropathy associated T-cell lymphoma (EATCL) Other types not associated with enteropathy
5 German Multicenter Study GIT NHL 02/96 Distribution of histologic subtypes in 393 patients with localized primary gastric lymphoma Koch et al. JCO, 2005
6 Distribution of WHO histologic types in localized GI-NHL at BCCA Intestine (N=91) Stomach (N=85) DLCL 70% 60% MALT type 7% 35% Follicular 17% --- Other types 6% 5% TN Shenkier and JM Connors, 2006
7 MALT lymphoma (Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid-Tissue ) HISTOLOGICAL FEATURES AND PHENOTYPE centrocyte-like cells (usually) lymphoepithelial lesions plasma cell differentiation scattered transformed blasts admixed non-neoplastic T-cell follicular colonisation sig (usually IgM + and IgD - ) CD20, CD21, CD35 positive; CD5, CD10, CD23 negative
8 The H. pylori and Gastric MALT Lymphoma Story 72-90% prevalence of H. pylori infection in gastric MALT lymphoma (Wotherspoon 1991, Nakamura 1997) high prevalence of both H. pylori infection and gastric MALT lymphomas in North-eastern Italy (Doglioni 1992) eradication of H. pylori leads to histological regression of low-grade gastric lymphoma (Wotherspoon 1993) previous H. pylori infection more likely in gastric lymphoma than in matched non-gastric lymphoma controls (Parsonnet 1994) molecular detection in previous gastritis specimens of the clonal B-cell that will give rise to the MALToma (Zucca 1998)
9 H. pylori and MALT lymphoma a model of tumor progression B B B B B B B B B H. pylori-dependent MALT lymphoma neutrophils activations with release of genotoxic free radicals genetic alterations H. pylori chronic gastritis B B B B B B B B-cell proliferation strain-specific stimulation contact-dependent B-cell stimulation antigen selection autoimmunity T T T T T mucosal T-cell proliferation additional genetic damages H. pylori-independent MALT lymphoma diffuse large B-cell lymphoma
10 Different chromosomal translocations affecting the same signalling pathway in MALT lymphoma rare t(1;14) BCL10 deregulation common t(11;18) CagA+ strains API2/MALT1 fusion NF-kB activation Antibiotic-resistant gastric lymphoma at non-gi sites t(14;18) MALT 1 deregulation? more recently described t(3;14) FOXP1 overexpression poorer outcome and higher risk of histological transformation
11 MALT lymphoma, one and the same: Extranodal Marginal Zone B-Cell Lymphoma of mucosa-associated lymphoid-tissue Low-grade MALT lymphoma MALToma Not the same: DLBCL arising at a MALT site (with or without any low-grade MALT component) NB: The term High-grade MALT should not be used!
12 Treatment options for gastric MALT lymphoma Non-randomised trials provide some evidence of activity for: Stage I and II Antibiotics Surgical excision Radiation Chemotherapy Rituximab Stage III and IV Chemotherapy Rituximab
13 Stage I gastric MALT lymphoma: Response to antibiotics Reference n staging % CR time No. of procedure to CR relapses (months) Wotherspoon, US Savio, CT Pinotti, CT Neubauer, CT±EUS Nobre Leitao, CT+EUS Steinbach, CT±EUS Montalban, CT±EUS Ruskone-Formestraux, CT+EUS Bertoni, CT
14 Response evaluation in gastric MALToma following anti-helicobacter therapy Complete histologic remission (CR) residual lymphoma cells cannot be detected and an empty lamina propria is found with only small basal clusters of lymphocytes and plasma cells Partial remission (PR) partial depletion of lymphoid cells from the lamina propria or focal lymphoepithelial destruction Neubauer A, J Natl Cancer Inst 1997
15 Wotherspoon s Histologic score for gastric MALT lymphoma (Lancet 1993) Score Description Histological features CR PR NC 0 normal scattered plasma cells in lamina propria 1 chronic active gastritis small clusters of lymphocytes in lamina propria; no lymphoid follicles; no LELs 2 chronic active gastritis prominent lymphoid follicles with with lymphoid follicles surrounding mantle zone and plasma cells; no LELs 3 suspicious infiltrate, lymphoid follicles surrounded by small probably reactive lymphocytes that infiltrate in lamina propria and occasionally into epithelium 4 suspicious infiltrate, lymphoid follicles surrounded by probably lymphoma CCL cells that infiltrate diffusely in lamina propria and into epithelium in small groups 5 Low Grade MALT dense diffuse infiltrate of CCL cells in lymphoma lamina propria with prominent LELs LEL = lymphoepithelial lesion; CCL = centrocyte-like
16 GELA score for gastric MALT lymphoma (Copie-Bergmann et al, Gut 2003) CR complete histological remission pmrd probable minimal residual disease rrd responding residual disease NC no change Normal or empty LP and/or fibrosis with absent or scattered plasma cells and small lymphoid cells in the LP, no LEL Empty LP and/or fibrosis with aggregates of lymphoid cells or lymphoid nodules in the LP/MM and/or SM, no LEL Focal empty LP and/or fibrosis with dense, diffuse or nodular lymphoid infiltrate, extending around glands in the LP, focal LEL or absent Dense, diffuse or nodular lymphoid infiltrate, LEL usually present
17 GI-NHL follow-up Endoscopic and histological remission does not mean cure PCR assay for the detection of monoclonal B-cells remained positive in approximately 50% of histological CR clinical relevance and prognostic significance of molecular remission still to be ascertained Thiede, 2001 Bertoni, 2002 wait-and-see policy: safe if a close follow-up can be performed The neoplastic clone can re-expand but without the H. pylori stimulus this may remain a self-limiting event transient histological and molecular relapses and/or persistent clonality without lymphoma progression or histologic transformation Isaacson, 1999 Fischbach, 2002 Wundisch, 2005
18 LY03 Trial IELSG patients registered, H.pylori eradicated with antibiotics in 97% 63% of patients with abnormal mucosa at registration achieved macroscopically normal gastric mucosa 56% histological lymphoma regression rate median time to lymphoma regression: 3-24 mos 3-year 5-year 5 year relapse relapse-free overall rate survival survival Observation 14% 79 % 98 % Chlorambucil 16 % 78 % 91 % Hancock et al. 9-ICML Lugano 2005
19 Prognostic factors (predicting a poor response to antibiotics) locally advanced disease (EUS) H. pylori-negative status t(11;18), nuclear BCL10 increased number of blasts and/or focal high-grade areas? concomitant autoimmune diseases? EUS staging in gastric MALT lymphoma Depth of parietal infiltration CR rate [95%CI] Mucosal 78% [52-94] Submucosa 43% [10-82] Muscularis propria 20% [0.5-71] Serosa 25% [0.6-80] No response in pts with nodal involvement Ruskone-Formestraux et al. 2001
20 Second-line Therapy Front-line antibiotics > 90% H.Pylori eradication ~ % histological CR < 10% recurrence? (problems with definition, increasing recurrences with longer follow-up?) How should we treat persistent or recurrent lymphoma after eradication therapy?
21 Consensus on 2 nd line Therapy? RT SX CT 7 Dutch centres European centres non-european De Jong et al. Ann Oncol,1999
22 Excellent prognosis regardless of treatment in patients with stage IE gastric MALT lymphoma Treatment Antibiotics % 94% (65-99) Local treatment a % 92% (57-99) Chemotherapy % 75% (32-93) Combined modality b % 80% (20-97) Total n 72 additional tumors (n of pts) 12 CR rate 74% 5-year OS (95% CI) 89% (76-96) a surgery ± RT b surgery+ adjuvant chemotherapy Pinotti et al, 1997
23 Surgical therapy of gastric MALT lymphoma in the studies that take account of the MALT concept the results of surgical resection alone are excellent with 5-year survival rates of 85%-95% Cogliatti et al, 1991 Ruskone-Formestraux et al, 1991 but a total gastrectomy should be considered since MALT lymphoma is often multifocal Wotherspoon et al, 1992 Acute complications Long-term morbidity (e.g., dumping syndrome)
24 Radiotherapy in gastric MALToma Author n RT dose (Gy) FFP Burgers, WA+ 20 boost 83% at 4 yr Schechter, % at 27 mo Tsang, % at 5 yr Yahalom, median 89% at 4 yr Hitchcock, median 78%, 100% local
25 Questions regarding RT Optimal RT volume, dose and technique? Does RT provide durable local control? Does this really translate to cure? In a very indolent condition, is the potential toxicity cost acceptable? (gastric and renal damage, risk of second malignancy) RT Toxicity can be reduced using 3D conformal techniques and minimizing the RT dose to the kidneys and the liver
26 Continuous oral administration of single alkylating agents in MALT lymphoma 24 patients, 17 stage I and 7 stage IV Cyclophosphamide or Chlorambucil for 8-24 mos. 100% ORR (75%CR) 5-year EFS: 50% 5-year OS: 75% 5 relapses at initial sites (1 with transformation) Hammel et al. JCO, 1995
27 Phase II study of Cladribine (2-CdA, 0.12 mg/kg/d x5, q28 d) 26 patients, 19 gastric and 7 non-gastric MALToma 100% ORR (84% CR); higher CR rate in gastric (100%) than extragastric (43%) hematologic toxicity grade 3 in 35% Disease-free survival at 6.7 years was 78% for the patients with gastric disease, and 33% for those with extragastric The use of purine analogs might however be associated with an increased risk of secondary MDS Jäger et al., 2002 and 2006
28 Questions regarding CT No randomised trials published The combination of Chlorambucil, Mitoxantrone and Prednisone as well as the classic CVP have been reported to be active and well-tolerated and Fludarabine in combination with Mitoxantrone has also been found to be extremely active (Wohrer 2003; Zinzani 2004) Aggressive anthracycline-containing regimens are usually reserved for patients with histological transformations or with bulky masses Given the indolent course of gastric MALT lymphomas the need for aggressive regimens remains controversial.
29 Rituximab in Gastric MALT NHL Response to treatment with single agent Rituximab (375 mg/m 2 /weekly x4) No of pts. (%) Complete response Partial Response 8 31 Stable Disease 6 23 good clinical activity of rituximab in gastric MALT lymphomas resistant/refractory to antibiotics or H. pylori-negative 11 of 12 CRs had stage I or II disease at study entry The t(11; 18)(q21; q21) was not a predictive marker of response. Martinelli et al. J Clin Oncol 2005
30 Provisional guidelines for the treatment of (gastric) MALToma Optimal therapy remains unresolved, but prognosis is usually excellent regardless of treatment: Initial antibiotic therapy in localized H.pylori-positive RT, CT and rituximab can be used in patients who do not respond to antibiotics. The choiche should consider the less toxic option for every single situation. Role of surgery to be redefined Rituximab to be further evaluated
31 INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG IELSG-19 Randomized trial in MALT lymphoma Chlorambucil alone vs Chlorambucil+ Rituximab vs Rituximab alone IELSG IELSG 25 phase II study of Bortezomib in pretreated MALT lymphomas Bortezomib 1,3 mg/m2 day 1, 4, 8, 11 in relapsed/refractory MALT lymphoma 1 prior systemic treatment (chemotherapy and/or immunotherapy) any extranodal site, any stage
32 Problems with surgery in GI- NHL 5-10% postoperative mortality rate with substantial immediate morbidity and long-term complications or discomfort related to gastrectomy Primary resectability rate of the study population is an important factor of positive selection: Surgery is possible only in 60-70% of cases because of disseminate disease or poor condition and only 50% of them can be completely resected Salles et al. Am J Med 90: 77-84, 1991 Law MM et al. J surgery Oncol 61: , 1996 Bartlett DL et al. Ann surgery 223: 53-62, 1996
33 Management of Diffuse Large B-Cell Lymphoma of the Stomach Surgery has, historically, been the initial procedure of choice because it simultaneously solved diagnostic and therapeutic problems. Since endoscopy and CT scan have become generally available, the necessity of surgery for biopsy and staging has disappeared. Having conservative approaches proven successful, the need for routine gastrectomy has been eliminated. Surgery does not necessarily prevent complications, as episodes of bleeding or perforation have also been reported despite surgical resection Risk of bleeding or perforation during chemotherapy generally overestimated
34 Treatment of gastric DLBCL at the IOSI Localised stages 3-4 cycles R-CHOP followed by IF-RT or 6 8 cycles of R-CHOP (conformational techniques to reduced RT toxicity) Antibiotic therapy alone is investigational but can be added to chemotherapy at the clinician s discretion. Advanced-stage patients 6 8 cycles of R-CHOP
35 Special situations Mantle cell lymphoma and follicular lymphoma of small intestine can both present with multiple lesions (multiple lymphomatous polyposis). The prognosis for mantle cell lymphoma is poor in spite of aggressive chemotherapy, similar to its nodal equivalent. Rectal presentations are less common than other sites in the lower intestinal tract. Treatment usually includes chemotherapy and RT. Abdominoperineal resection should be discouraged, as there is no evidence that it improves local control or survival.
36 Special situations (cont.) The clinical course of EATCL is very unfavourable with death usually resulting from multifocal intestinal perforations due to ulcerating lymphoma. Very aggressive treatment is usually needed. Resolution of early-stage IPSID after antimicrobial therapy is possible and Campylobacter jejuni has been recently associated with this disease
MALT LYMPHOMA. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma
MALT LYMPHOMA Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Madrid, 25-26 November 2016 Disclosuresof commercial support Roche Gilead Marginal zone B-cell lymphomas
More informationMALT LYMPHOMA. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma
MALT LYMPHOMA Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Lugano, 3-4 November 2017 Disclosures: Roche: honoraria Gilead: travel grant ESMO Preceptorship on Lymphoma
More informationTreatment: Gastric MALT lymphoma Anastasios Stathis, M.D.
Treatment: Gastric MALT lymphoma Anastasios Stathis, M.D. Phase I and Lymphoma Unit Oncology Ins6tute of Southern Switzerland Bellinzona, Switzerland Gastric MALT lymphoma MALT lymphomas: approximately
More informationPatient underwent hemicolectomy: 7 x 4.5 cm intusscepted segment of ileum in colon - mucosal
Extranodal Lymphomas Rena Buckstein Odette Cancer Center Case: JT 69 yo male COO software company PMHx: basal cell back, cholesterol Presents to ER with severe abdominal pain, bloody diarrhea x 2d In ER
More informationRegression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori
Gut and Liver, Vol. 6, No. 2, April 2012, pp. 270-274 CASE REPORT Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori Soo-Kyung Park, Hwoon-Yong Jung, Do Hoon Kim,
More informationPRIMARY GASTRIC LYMPHOMA: CASE REPORT WITH REVIEW OF LITERATURE
PRIMARY GASTRIC LYMPHOMA: CASE REPORT WITH REVIEW OF LITERATURE Rana K. Sherwani, *Kafil Akhtar, Noorin Zaidi, Anjum Ara Department of Pathology, J.N. Medical College, Aligarh Muslim University, Aligarh,
More informationGastric MALT-lymphoma and Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 89 94. Gastric MALT-lymphoma and Helicobacter pylori infection E. BAYERDO RFFER, S. MIEHLKE, A. NEUBAUER & M. STOLTE* Department of Gastroenterology, Hepatology
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationLimited Role of Bone Marrow Aspiration and Biopsy in the Initial Staging Work-up of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma in Korea
Gut and Liver, Vol. 8, No. 6, November 2014, pp. 637-642 ORiginal Article Limited Role of Bone Marrow Aspiration and Biopsy in the Initial Staging Work-up of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationKey words : low-grade MALT lymphoma, epithelial change, empty lamina propria, B-cell clonality, H. pylori, eradication, long-term follow-up
Department of Pathology, The University of Tokushima School of Medicine, Tokushima, Japan ; Department of Oral and Maxillofacial Surgery, The University of Tokushima School of Dentistry, Tokushima, Japan
More informationFOLLICULARITY in LYMPHOMA
FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationHistopathology: gastritis and peptic ulceration
Histopathology: gastritis and peptic ulceration These presentations are to help you identify, and to test yourself on identifying, basic histopathological features. They do not contain the additional factual
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationIndolent B-Cell Non-Hodgkin s Lymphomas
Review Article [1] December 01, 1997 Myelodysplastic Syndromes [2] By John E. Seng, MD [3] and Bruce A. Peterson, MD [4] The indolent B-cell non-hodgkin s lymphomas are a diverse group of disorders that
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationNodular lymphocyte predominant Hodgkin lymphoma. Lymphoma Tumor Board. January 5, 2018
Nodular lymphocyte predominant Hodgkin lymphoma Lymphoma Tumor Board January 5, 2018 Etiology Subtypes of Classical Hodgkin Lymphoma (chl)* Nodular sclerosing HL Most common subtype Composed of large tumor
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationINTRODUCTION. See editorial on page 659. Background/Aims: We investigated the effectiveness of
Gut and Liver, Vol. 10, No. 5, September 2016, pp. 706-713 ORiginal Article Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-negative and Disseminated
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationGastric MALT lymphoma and Helicobacter pylori
ÐÑÁÊÔÉÊÁ GASTRIC 5ïõ MALT ÐÁÍÅËËÇÍÉÏÕ LYMPHOMA ÓÕÍÅÄÑÉÏÕ AND HELICOBACTER ÃÉÁ ÔÏ ÅËÉÊÏÂÁÊÔÇÑÉÄÉÏ PYLORI ÔÏÕ ÐÕËÙÑÏÕ ÁèÞíá, 2000 Gastric MALT lymphoma and Helicobacter pylori Andrew Wotherspoon Introduction
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationEGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT
Gut Online First, published on February 11, 2011 as 10.1136/gut.2010.224949 Guidelines For numbered affiliations and full list of contributors see end of article. Correspondence to Agnès Ruskoné-Fourmestraux,
More informationTwo Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type
Med. J. Kagoshima Univ., Vol. 47, Suppl. 2. 93-96, November, 1995 Case Report Two Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type Mitsuharu NOMOTO1, Hiroshi SHIRAHAMA1,
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationLYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationSmall B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationCase Report Mantle Cell Lymphoma Mimicking Rectal Carcinoma
Case Reports in Hematology, Article ID 621017, 4 pages http://dx.doi.org/10.1155/2014/621017 Case Report Mantle Cell Lymphoma Mimicking Rectal Carcinoma Engin Kelkitli, 1 Hilmi Atay, 2 Levent YJldJz, 3
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationDOI: /jemds/2014/1882 CASE REPORT
NON HODGKIN'S LYMPHOMA OF STOMACH WITH SPONTANEOUS PERFORATION: A WITH REVIEW OF LITERATURE Rishikant Vashistha 1, Abhishek Kansal 2, S.M. Datey 3, Vikramaditya Singh 4 HOW TO CITE THIS ARTICLE: Rishikant
More informationMucosa-associated lymphoid tissue lymphoma of the urinary bladder
DOI 10.1007/s13691-012-0041-2 CASE REPORT Mucosa-associated lymphoid tissue lymphoma of the urinary bladder Taeko Matsuoka Takayuki Yoshino Yoshiharu Fukuhara Naoto Miyanaga Kuniyuki Oka Reizo Nagayama
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 31 NOVEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication Thomas Wündisch, Christian
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationEQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH
EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH CASE E1 M: 68 yrs Left destructive sinonasal lesion.?lymphoma?adenocarcinoma CD20 CD10 BCL6 MIB1 Answers Diffuse large B cell
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationPrimary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationBACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA
BACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA General Non-Hodgkin s lymphomas (NHLs) encompass several unique malignant lymphoid disease entities that vary in clinical behavior, morphologic appearance,
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationRituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationGela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
research paper Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice Christiane Copie-Bergman, 1,2,3 Andrew C.
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationCASE REPORTS INTRODUCTION
CASE REPORT Clin Endosc 2013;46:288-292 Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2013.46.3.288 Open Access Two Cases of Diffuse Large B-Cell Lymphomas in the Cervical
More informationConjunctival CD5+ MALT lymphoma and review of literatures
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Conjunctival CD5+ MALT lymphoma and review of literatures M Fard Citation M Fard. Conjunctival CD5+ MALT lymphoma and review of literatures.
More informationPredictive factors for regression of gastric MALT lymphoma after anti-helicobacter pylori treatment
Gut 2001;48:297 303 297 PAPERS Predictive factors for regression of gastric MALT lymphoma after anti-helicobacter pylori treatment A Ruskoné-Fourmestraux, A Lavergne, P H Aegerter, F Megraud, L Palazzo,
More informationClinical features and management of primary colonic lymphoma
Formosan Journal of Surgery (2012) 45, 73e77 Available online at www.sciencedirect.com journal homepage: www.e-fjs.com MINI-REVIEW Clinical features and management of primary colonic lymphoma Shih-Ching
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationThe gastrointestinal (GI) tract is a site of continual
Lymphoproliferative Disorders of the Gastrointestinal Tract Brian F. Skinnider, MD, FRCPC Context. The diagnosis of gastrointestinal lymphoproliferative disorders can be challenging because of the small
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationBurkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationLocalised gastrointestinal diffuse large B cell lymphomas; Does surgical approach still exist?
HeSMO 6(1) 2015 10 17 DOI: 10.1515/fco-2015-0003 Forum of Clinical Oncology Localised gastrointestinal diffuse large B cell lymphomas; Does surgical approach still exist? Abeer Ibrahim 1*, Ali Zedan 2,
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationRadiotherapy of Follicular Lymphoma: Updated Role and New Rules
Current Treatment Options in Oncology (2014) 15:262 268 DOI 10.1007/s11864-014-0286-4 Lymphoma (A Engert, Section Editor) Radiotherapy of Follicular Lymphoma: Updated Role and New Rules Joachim Yahalom,
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More informationRole of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i3.684 World J Gastroenterol 2014 January 21; 20(3): 684-698 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More information